Mount Sinai Department of Dermatology | Strategic Alliance Partners

The article highlights the immense global burden of atopic dermatitis, the most common chronic inflammatory skin disease, affecting over 200 million individuals worldwide.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

Many patients with severe AD are unaware of newer, more effective treatments.

Traditional descriptions often cater to lighter skin, necessitating updates to better serve diverse populations.

Nanette Silverberg, MD, discusses new treatments for pediatric vitiligo, including JAK inhibitors and surgical advancements.

“The most important tip as a physician, when you talk to the patient, sit down. Even if you sit down for 5 minutes, it's worth almost 5 hours,’ Leon Kircik, MD, said in his interview with Dermatology Times at SBS 2025.

According to Silverberg, emotional resilience, social support, and purposeful activities help adolescents cope with acne-related stress.

Nanette Silverberg, MD, highlights new dermatology advancements and the significance of conferences like MOPD in shaping the future of treatment.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Kim, who received the Marion B. Sulzberger Award at the 2024 American Academy of Dermatology Annual Meeting, discussed itch research an implications for clinical practice.

The partnership and newly-established center will develop dermatological research and delve into skin aging, skin allergies, and inflammatory or eczematous conditions.

Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.

Mark Lebwohl, MD, discusses his SDPA Annual Summer Dermatology Conference session, "Inflammatory Dermatoses: A Case-Based Review."

Zeichner reviewed his top 3 acne treatment pearls at the Fall Clinical Dermatology Conference for PAs and NPs.